文献速递皮肤肿瘤

TET2缺失通过诱导PGC-1α表达和氧化磷酸化促进皮肤黑色素瘤侵袭行为

Loss of ten-eleven translocation 2 (TET2) facilitates aggressive behaviour in cutaneous melanoma by inducing peroxisome proliferator-activated receptor-γ coactivator 1α expression and oxidative phosphorylation.
PubMed 文献 · Br J Dermatol · 2026-01-01

该研究分析368例黑色素瘤转移灶和102例原发瘤的RNA测序数据,发现TET2低表达肿瘤中PGC-1α表达和OXPHOS激活显著上调,且TET2/5-hmC与PPARGC1A/PGC-1α表达呈负相关。体外和体内实验证实TET2缺失促进迁移侵袭和转移,并导致MAPK通路抑制耐药,但增加对OXPHOS抑制的敏感性。

要点

  • TET2低表达黑色素瘤中PGC-1α/OXPHOS上调,促进侵袭转移和MAPK抑制剂耐药。
  • TET2缺失肿瘤对OXPHOS抑制更敏感,提示可靶向治疗机会。
  • TET2/5-hmC可能作为黑色素瘤侵袭性和治疗反应的生物标志物。

核心结论

  • TET2缺失通过表观遗传机制上调PGC-1α/OXPHOS,驱动黑色素瘤代谢重编程、侵袭转移和MAPK抑制剂耐药,并赋予OXPHOS抑制敏感性。

研究设计与样本

  • 分析368例黑色素瘤转移灶和102例原发瘤RNA测序数据,按TET2表达分为TET2-low和TET2-high。
  • 使用33例临床标本组织芯片和209例原发瘤公共基因表达数据集验证。
  • 体外和体内实验使用TET2和PGC-1α表达改变的黑色素瘤细胞系。
  • 采用hMeDIPseq和甲基化DNA免疫沉淀测序评估PPARGC1A的5-hmC和5-mC水平。

主要发现

  • TET2-low转移灶和原发瘤中PGC-1α表达和OXPHOS激活显著上调。
  • 组织芯片和基因表达研究显示TET2/5-hmC与PPARGC1A/PGC-1α表达及OXPHOS呈负相关。
  • 黑色素瘤中PPARGC1A上游活性增强子处5-hmC水平显著低于痣,TET2-low细胞低于TET2-high细胞,表达催化失活TET2的细胞低于表达野生型TET2的细胞。
  • 抑制PGC-1α表达和OXPHOS激活可减轻体外迁移侵袭和体内转移。
  • TET2缺失与MAPK通路抑制耐药相关,并增强对OXPHOS抑制的敏感性。

临床怎么用

  • 检测肿瘤TET2/5-hmC水平可能帮助识别可能受益于OXPHOS抑制治疗的黑色素瘤患者。
  • 对于TET2缺陷的黑色素瘤,可考虑联合OXPHOS抑制以克服MAPK抑制剂耐药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The induction of peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α; encoded by PPARGC1A) expression and activation of oxidative phosphorylation (OXPHOS) is associated with disease progression and treatment resistance in patients with cutaneous melanoma. Loss of the TET2 (ten-eleven translocation 2)/5-hydroxymethylcytosine (5-hmC) epigenetic pathway is linked to melanoma aggressiveness, although the underlying mechanisms remain unclear. OBJECTIVES: To explore a relationship between TET2-mediated DNA hydroxymethylation and the induction of PPARGC1A/PGC-1α expression and activation of OXPHOS in melanoma. METHODS: RNA sequencing data from 368 melanoma metastases and 102 primary melanoma tumours were analysed, with tumours categorized as 'TET2-low' or 'TET2-high', based on TET2 gene expression. Differential gene expression and gene set enrichment analyses were done, with further validation using a tissue microarray comprised of 33 clinical specimens and a publicly available gene expression dataset from 209 primary tumours. Confirmatory in vitro and in vivo studies were performed using melanoma cell lines with altered TET2 and PGC-1α expression. 5-hmC and 5-methylcytosine levels at PPARGC1A were assessed using hydroxymethylated (hMeDIPseq) and methylated DNA immunoprecipitation sequencing. RESULTS: PGC-1α expression and activation of OXPHOS were significantly upregulated in TET2-low metastases and primary tumours. Tissue microarray analysis and gene expression studies showed an inverse relationship between TET2/5-hmC and PPARGC1A/PGC-1α expression and OXPHOS. In vitro and in vivo, PPARGC1A/PGC-1α expression and activation of OXPHOS was higher in TET2-low cells. hMeDIPseq identified significantly lower 5-hmC levels at an upstream PPARGC1A active enhancer in melanoma compared with naevi, in TET2-low compared with TET2-high cells and in cells expressing catalytically inactive TET2 compared with cells expressing wildtype TET2. Inhibition of PGC-1α expression and activation of OXPHOS mitigated migration and invasion in vitro and metastasis in vivo; TET2 loss was associated with resistance to mitogen-activated protein kinase (MAPK) pathway inhibition and enhanced sensitivity to OXPHOS inhibition. CONCLUSIONS: Loss of TET2 promotes activation of PGC-1α/OXPHOS in melanoma, driving metabolic reprogramming that supports tumour progression and resistance to MAPK inhibition in a subset of tumours. Importantly, this phenotype renders TET2-deficient melanomas selectively vulnerable to OXPHOS inhibition, identifying an actionable therapeutic opportunity. These findings establish an epigenetic-metabolic axis as a critical determinant of melanoma aggressiveness and highlight TET2/5-hmC as a potential biomarker and a targetable pathway. Cutaneous melanoma is a deadly form of skin cancer. It begins in pigment-producing skin cells called melanocytes. Melanoma is becoming more common worldwide. Advanced stages of the disease can be life-threatening if it spreads to other parts of the body. This study was done in the USA. We wanted to understand how changes in a gene called ‘TET2’ affect how melanoma behaves and whether these changes could be targeted with new treatments. The TET2 gene is involved in a process called ‘DNA hydroxymethylation’. This process helps control how some other genes are turned on or off. The TET2 gene also instructs for a protein with the same name to be produced by cells. We looked at tumour samples from hundreds of people with melanoma. We found that when TET2 protein levels were low, another gene called ‘PPARGC1A’ was more active. This gene encodes a protein called ‘PGC-1α’. The PGC-1α protein increases energy production in cells through a process called ‘oxidative phosphorylation’ (OXPHOS). This gives cancer cells fuel to spread. We found that cells with less TET2 protein were more likely to spread and resist standard treatments. However, when we blocked OXPHOS, aggressive cells became less able to invade and spread to other parts of the body. Our results show that when melanoma cells lose TET2 protein, they activate OXPHOS. This helps them spread and resist treatment. This also creates a weakness that we can target with certain drugs. In future, testing tumours for TET2 protein levels might help doctors identify patients with melanoma who could benefit from treatments that target the OXPHOS process.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Fischer GM, Fang R, Xu S, et al. Loss of ten-eleven translocation 2 (TET2) facilitates aggressive behaviour in cutaneous melanoma by inducing peroxisome proliferator-activated receptor-γ coactivator 1α expression and oxidative phosphorylation. Br J Dermatol. 2026. PMID: 41016027. doi:10.1093/bjd/ljaf378

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。